{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058279","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.924521+00:00","generated_at":"2026-06-08T23:49:16.292612+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eledon reports Phase 1b data: tegoprubart prevents rejection with eGFR >70 in kidney transplant","bullets":["Data from 11 participants showed no graft loss or death; one mild T cell mediated rejection (Banff 1a) on day 99 treated successfully.","Aggregate mean eGFR above 70 mL/min/1.73m2 after day 90; no hyperglycemia, new onset diabetes, tremor, or CMV infection seen.","Phase 2 BESTOW trial comparing tegoprubart vs. tacrolimus underway; enrollment of ~120 participants expected to complete end of 2024.","One participant completed 1-year study with eGFR of 91 at day 374 and enrolled in Phase 2 open-label extension."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058279","json":"https://secwatch.observer/filing/0000950170-23-058279.json","markdown":"https://secwatch.observer/filing/0000950170-23-058279.md","text":"https://secwatch.observer/filing/0000950170-23-058279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023058279/0000950170-23-058279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023058279/eldn-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:49:16.292612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}